Investigation of the change in seroprevalence of viral hepatitis in patients receiving hemodialysis treatment over the years: A Single-Center Study

Gaziantep Islam Science and Technology University Pub Date : 2023-09-08 DOI:10.46871/eams.1229510

Safiye KOÇULU DEMİR, Tülin AKAGÜN

{"title":"Investigation of the change in seroprevalence of viral hepatitis in patients receiving hemodialysis treatment over the years: A Single-Center Study","authors":"Safiye KOÇULU DEMİR, Tülin AKAGÜN","doi":"10.46871/eams.1229510","DOIUrl":null,"url":null,"abstract":"Objective: In this study, it was aimed to evaluate HBV, HCV, and HIV seroprevalence and their 9-year changes in patients receiving hemodialysis (HD) treatment in the Giresun province in Turkey. Material-Methods: A total of 607 patients over the age of 18 who received hemodialysis treatment in Giresun – Turkey, provincial and district hospitals in 2013 and 2022 were included in our study. The files of the patients were reviewed retrospectively. Demographic characteristics of the patients and serology results of HBV, HCV, HDV, and HIV were recorded. The data was evaluated using the IBM SPSS Statistics 25.0 program. Results: A total of 607 patients, 385 of whom received HD treatment in 2013 and 222 who received HD treatment in 2022, were included in the study. 230 (59.7%) in 2013 and 135 (60.8%) in 2022 of male patients. While the mean age of the patients was 60.26±14 years in 2013, it was 63.08±13.18 years in 2022. In 2013, HBsAg positivity was detected in 9 (2.3%), HBV-DNA positivity in 4 (44.4%), anti-HCV positivity in 31 (8.1%), and HCV-RNA positivity in 8 (25.8%) patients. In 2022, HBsAg positivity was detected in 4 (1.8%), HBV DNA positivity in 2 (50%), and anti-HCV positivity in 31 (8.1%) patients. Compared with dialysis duration, the anti-HCV positivity rate was significantly increased in patients with long dialysis duration (p","PeriodicalId":335844,"journal":{"name":"Gaziantep Islam Science and Technology University","volume":"44 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaziantep Islam Science and Technology University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46871/eams.1229510","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: In this study, it was aimed to evaluate HBV, HCV, and HIV seroprevalence and their 9-year changes in patients receiving hemodialysis (HD) treatment in the Giresun province in Turkey. Material-Methods: A total of 607 patients over the age of 18 who received hemodialysis treatment in Giresun – Turkey, provincial and district hospitals in 2013 and 2022 were included in our study. The files of the patients were reviewed retrospectively. Demographic characteristics of the patients and serology results of HBV, HCV, HDV, and HIV were recorded. The data was evaluated using the IBM SPSS Statistics 25.0 program. Results: A total of 607 patients, 385 of whom received HD treatment in 2013 and 222 who received HD treatment in 2022, were included in the study. 230 (59.7%) in 2013 and 135 (60.8%) in 2022 of male patients. While the mean age of the patients was 60.26±14 years in 2013, it was 63.08±13.18 years in 2022. In 2013, HBsAg positivity was detected in 9 (2.3%), HBV-DNA positivity in 4 (44.4%), anti-HCV positivity in 31 (8.1%), and HCV-RNA positivity in 8 (25.8%) patients. In 2022, HBsAg positivity was detected in 4 (1.8%), HBV DNA positivity in 2 (50%), and anti-HCV positivity in 31 (8.1%) patients. Compared with dialysis duration, the anti-HCV positivity rate was significantly increased in patients with long dialysis duration (p

查看原文本刊更多论文

多年来接受血液透析治疗的患者病毒性肝炎血清患病率变化的调查:一项单中心研究

目的:在这项研究中，旨在评估在土耳其Giresun省接受血液透析(HD)治疗的患者中HBV、HCV和HIV的血清患病率及其9年变化。材料-方法:选取2013年和2022年在土耳其Giresun及省、区医院接受血液透析治疗的607例18岁以上患者作为研究对象。对患者资料进行回顾性分析。记录患者的人口学特征和HBV、HCV、HDV、HIV的血清学结果。使用IBM SPSS Statistics 25.0程序对数据进行评估。结果:共纳入607例患者，其中2013年接受HD治疗的患者385例，2022年接受HD治疗的患者222例。2013年230例(59.7%)，2022年135例(60.8%)。2013年患者平均年龄为60.26±14岁，2022年患者平均年龄为63.08±13.18岁。2013年，HBsAg阳性9例(2.3%)，HBV-DNA阳性4例(44.4%)，抗- hcv阳性31例(8.1%)，HCV-RNA阳性8例(25.8%)。2022年，检测到HBsAg阳性4例(1.8%)，HBV DNA阳性2例(50%)，抗hcv阳性31例(8.1%)。与透析时间相比，透析时间越长，抗- hcv阳性率越高(p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gaziantep Islam Science and Technology University

自引率

0.00%

发文量